Pulmonary fibrosis in rheumatoid arthritis: A review of clinical features and therapy
| Autor: | Robert A. Roschmann, Ralph J. Rothenberg |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Pulmonary Fibrosis Antineoplastic Agents Gastroenterology Pulmonary function testing Arthritis Rheumatoid Idiopathic pulmonary fibrosis Rheumatology Adrenal Cortex Hormones Fibrosis Internal medicine Azathioprine Pulmonary fibrosis medicine Humans Restrictive lung disease Aged Lung medicine.diagnostic_test business.industry Penicillamine Respiratory disease Middle Aged Prognosis medicine.disease Respiratory Function Tests Radiography Serology Anesthesiology and Pain Medicine Bronchoalveolar lavage medicine.anatomical_structure Female business |
| Zdroj: | Seminars in Arthritis and Rheumatism. 16:174-185 |
| ISSN: | 0049-0172 |
| DOI: | 10.1016/0049-0172(87)90020-5 |
| Popis: | During the past four decades there has been a growing appreciation of the frequency of pulmonary abnormalities associated with RA. Approximately 30% to 40% of patients with RA demonstrate either radiographic or pulmonary function abnormalities indicative of interstitial fibrosis or restrictive lung disease. The severity of pulmonary fibrosis is not associated with rheumatologic symptoms or the duration of the associated RA, nor is there any clear relation to the extraarticular features of RA or serologic findings. Survival rates in patients with coexisting RA and pulmonary fibrosis are similar to those of patients with idiopathic pulmonary fibrosis. However, the spectrum of disease activity is quite variable. The majority of patients with progressive pulmonary symptomatology, when treated with corticosteroids, will have equivocal results. Some patients appear to respond to immunosuppressive or cytotoxic medications. The role of macrophages may be central to the injury to lung. Recent studies suggest a potential treatment role for cyclosporine, which may be able to interrupt lymphocyte-stimulated macrophage activation, and thus, fibroblast-mediated fibrosis in patients with pulmonary interstitial fibrosis. Bronchoalveolar lavage studies may delineate subgroups of patients who are more likely to respond to immunosuppressive agents, especially when treatment is started early. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|